Ibrahim Azar

480 total citations
24 papers, 236 citations indexed

About

Ibrahim Azar is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ibrahim Azar has authored 24 papers receiving a total of 236 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ibrahim Azar's work include Neuroendocrine Tumor Research Advances (4 papers), Lung Cancer Research Studies (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Ibrahim Azar is often cited by papers focused on Neuroendocrine Tumor Research Advances (4 papers), Lung Cancer Research Studies (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Ibrahim Azar collaborates with scholars based in United States, Canada and Japan. Ibrahim Azar's co-authors include Hélène Sénéchal, François Coutlée, Jacques Archambault, David Gagnon, Thibault Mésplède, Syed Mehdi, Syed J. Mehdi, Mohammed Najeeb Al Hallak, Jami Fukui and Ammar Sukari and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Ibrahim Azar

23 papers receiving 229 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ibrahim Azar United States 9 135 87 76 45 32 24 236
Şahin Laçin Türkiye 10 98 0.7× 69 0.8× 53 0.7× 38 0.8× 46 1.4× 37 242
Shannon C. Trotter United States 9 170 1.3× 75 0.9× 127 1.7× 13 0.3× 31 1.0× 14 299
Samantha Armstrong United States 10 144 1.1× 82 0.9× 41 0.5× 59 1.3× 64 2.0× 21 277
Veronika Kanitz Germany 8 74 0.5× 69 0.8× 51 0.7× 16 0.4× 32 1.0× 9 264
Malin Sternby Eilard Sweden 10 129 1.0× 47 0.5× 81 1.1× 45 1.0× 75 2.3× 27 314
Mushfiq Hassan Shaikh Canada 12 123 0.9× 133 1.5× 83 1.1× 35 0.8× 58 1.8× 32 378
Thaniya Sricharunrat Thailand 11 78 0.6× 75 0.9× 84 1.1× 63 1.4× 86 2.7× 21 288
Francesca Aroldi Italy 10 186 1.4× 53 0.6× 42 0.6× 66 1.5× 28 0.9× 36 262
Teresa Smit South Africa 10 141 1.0× 68 0.8× 33 0.4× 31 0.7× 43 1.3× 38 304
Milissa U. Jones United States 4 57 0.4× 44 0.5× 67 0.9× 22 0.5× 25 0.8× 13 195

Countries citing papers authored by Ibrahim Azar

Since Specialization
Citations

This map shows the geographic impact of Ibrahim Azar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ibrahim Azar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ibrahim Azar more than expected).

Fields of papers citing papers by Ibrahim Azar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ibrahim Azar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ibrahim Azar. The network helps show where Ibrahim Azar may publish in the future.

Co-authorship network of co-authors of Ibrahim Azar

This figure shows the co-authorship network connecting the top 25 collaborators of Ibrahim Azar. A scholar is included among the top collaborators of Ibrahim Azar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ibrahim Azar. Ibrahim Azar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reuss, Joshua E., Sara Kuruvilla, Nofisat Ismaila, et al.. (2025). Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1. Journal of Clinical Oncology. 43(24). e31–e44. 1 indexed citations
2.
Kaur, Jasmeet, Moazzam Shahzad, Ibrahim Azar, et al.. (2025). Tarlatamab-induced immune-related adverse events: Retrospective real-world pharmacovigilance study using FAERS database.. Journal of Clinical Oncology. 43(16_suppl).
3.
Liu, Bolun, et al.. (2024). Clinical profile and response to adjuvant treatments in patients with follicular dendritic cell sarcoma in the United States: Insights from SEER analysis.. Journal of Clinical Oncology. 42(16_suppl). e23537–e23537. 1 indexed citations
4.
Khan, Husain Yar, Misako Nagasaka, Amro Aboukameel, et al.. (2023). Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS G12C-Mutant Pancreatic and Lung Cancers. Molecular Cancer Therapeutics. 22(12). 1422–1433. 5 indexed citations
5.
Uddin, Md. Hafiz, Mohammed Najeeb Al Hallak, Husain Yar Khan, et al.. (2023). Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model. Clinical and Translational Medicine. 13(12). e1513–e1513. 11 indexed citations
6.
Azar, Ibrahim, Biplab K. Saha, Seongho Kim, et al.. (2023). The Role of Surgery in Stage I Small Cell Lung Cancer: A National VA Database Analysis. Clinical Lung Cancer. 24(5). e179–e186. 3 indexed citations
7.
Azar, Ibrahim, Stephani C. Wang, Dawn Lombardo, et al.. (2022). Preferences and Attitudes of Cardiologists in Management of Patients with Cancer. SHILAP Revista de lepidopterología. 3(1). 279–286. 2 indexed citations
8.
Azar, Ibrahim, Seongho Kim, Biplab K. Saha, et al.. (2022). Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans. JAMA Network Open. 5(10). e2237699–e2237699. 14 indexed citations
9.
Azar, Ibrahim, et al.. (2021). Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. SHILAP Revista de lepidopterología. Volume 12. 103–114. 22 indexed citations
10.
11.
Kurtz, Daniel, et al.. (2020). Xylophagia (paper eating): A rare form of pica. SHILAP Revista de lepidopterología. 8(12). 3546–3547. 4 indexed citations
12.
Azar, Ibrahim, et al.. (2019). Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study. Journal of Gastrointestinal Oncology. 10(4). 703–711. 24 indexed citations
13.
Azar, Ibrahim, et al.. (2019). A Case of Aggressive Multiple Myeloma with Extramedullary Involvement of the Female Reproductive System, Thyroid and Breasts. SHILAP Revista de lepidopterología. 2019. 1–5. 2 indexed citations
14.
Azar, Ibrahim, et al.. (2019). Durvalumab-Induced Hyperprogressive Disease in Nonmetastatic Lung Cancer. Journal of Oncology Practice. 15(4). 217–219. 3 indexed citations
15.
Azar, Ibrahim, et al.. (2018). Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: A nationwide study.. Journal of Clinical Oncology. 36(4_suppl). 507–507. 1 indexed citations
16.
Azar, Ibrahim, et al.. (2017). Sunitinib‐Induced Acute Interstitial Nephritis in a Thrombocytopenic Renal Cell Cancer Patient. Case Reports in Oncological Medicine. 2017(1). 6328204–6328204. 6 indexed citations
17.
Azar, Ibrahim, et al.. (2017). Squamous Cell Lung Carcinoma Presenting as Melena: A Case Report and Review of the Literature. Rare Tumors. 9(3). 85–88. 8 indexed citations
18.
Daniels, Sylvanne, Natalie J Ward, Carlos E Melendez-Peña, et al.. (2015). HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs. RNA Biology. 12(2). 123–135. 11 indexed citations
19.
Gatignol, Anne, et al.. (2014). Competition between HIV-1-encoded RRE RNA and miRNA-TRBP interactions alters RNA interference activity and gene expression. BMC Infectious Diseases. 14(S2). 2 indexed citations
20.
Azar, Ibrahim, et al.. (1999). A Mutation in the Promoter of the Multidrug Resistance Gene (MDR1) in Human Hematological Malignancies may Contribute to the Pathogenesis of Resistant Disease. Advances in experimental medicine and biology. 457. 71–75. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Şahin Laçin Breakdown of academic impact, for papers by Shannon C. Trotter Breakdown of academic impact, for papers by Samantha Armstrong Breakdown of academic impact, for papers by Veronika Kanitz Breakdown of academic impact, for papers by Malin Sternby Eilard Breakdown of academic impact, for papers by Mushfiq Hassan Shaikh Breakdown of academic impact, for papers by Thaniya Sricharunrat Breakdown of academic impact, for papers by Francesca Aroldi Breakdown of academic impact, for papers by Teresa Smit Breakdown of academic impact, for papers by Milissa U. Jones
Rankless by CCL
2026